KR20130126380A - Medicinal herbs compositions for anti-obesity - Google Patents
Medicinal herbs compositions for anti-obesity Download PDFInfo
- Publication number
- KR20130126380A KR20130126380A KR1020120050479A KR20120050479A KR20130126380A KR 20130126380 A KR20130126380 A KR 20130126380A KR 1020120050479 A KR1020120050479 A KR 1020120050479A KR 20120050479 A KR20120050479 A KR 20120050479A KR 20130126380 A KR20130126380 A KR 20130126380A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- obesity
- ephedra
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000003579 anti-obesity Effects 0.000 title claims description 3
- 235000008216 herbs Nutrition 0.000 title 1
- 208000008589 Obesity Diseases 0.000 claims abstract description 48
- 235000020824 obesity Nutrition 0.000 claims abstract description 48
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 21
- 241000018646 Pinus brutia Species 0.000 claims abstract description 21
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 21
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 16
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 16
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 241000218671 Ephedra Species 0.000 claims description 19
- 235000013372 meat Nutrition 0.000 claims description 18
- 244000020518 Carthamus tinctorius Species 0.000 claims description 14
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 14
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 13
- 210000004207 dermis Anatomy 0.000 claims description 13
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 12
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 12
- 229940010454 licorice Drugs 0.000 claims description 12
- 241001061264 Astragalus Species 0.000 claims description 10
- 241000202807 Glycyrrhiza Species 0.000 claims description 10
- 210000004233 talus Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000411851 herbal medicine Species 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 241000283074 Equus asinus Species 0.000 claims description 2
- 241000238413 Octopus Species 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 4
- 240000002045 Guettarda speciosa Species 0.000 claims 2
- 206010063409 Acarodermatitis Diseases 0.000 claims 1
- 241000447727 Scabies Species 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000005687 scabies Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 206010033307 Overweight Diseases 0.000 abstract description 4
- 240000001810 Angelica gigas Species 0.000 abstract description 3
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 3
- 230000037396 body weight Effects 0.000 abstract description 3
- 244000306301 Caesalpinia sappan Species 0.000 abstract description 2
- 235000015162 Caesalpinia sappan Nutrition 0.000 abstract description 2
- 241000282461 Canis lupus Species 0.000 abstract description 2
- 241000555678 Citrus unshiu Species 0.000 abstract description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 abstract description 2
- 241000657480 Crataegus pinnatifida Species 0.000 abstract description 2
- 235000000525 Dimocarpus longan Nutrition 0.000 abstract description 2
- 240000006890 Erythroxylum coca Species 0.000 abstract description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 2
- 241001643409 Sinomenium acutum Species 0.000 abstract description 2
- 240000008042 Zea mays Species 0.000 abstract description 2
- 235000008957 cocaer Nutrition 0.000 abstract description 2
- 241001675349 Artemisia dubia var. asiatica Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 abstract 1
- 241000132011 Atractylodes lancea Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 abstract 1
- 241001465251 Ephedra sinica Species 0.000 abstract 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 241000612118 Samolus valerandi Species 0.000 abstract 1
- 235000007244 Zea mays Nutrition 0.000 abstract 1
- 229940089639 cornsilk Drugs 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 239000001231 zea mays silk Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 14
- 230000004580 weight loss Effects 0.000 description 10
- 241001092040 Crataegus Species 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 244000061520 Angelica archangelica Species 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000001882 diuretic effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 235000003642 hunger Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 235000001916 dieting Nutrition 0.000 description 3
- 230000037228 dieting effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000010204 pine bark Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000121157 Achyranthes japonica Species 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 241001435059 Artemisia argyi Species 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 244000065027 Artemisia princeps Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- HFTWTHSIMCSLFQ-CMLLUXCUSA-N Glabric acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@](C)(C(O)=O)[C@H](O)C[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C HFTWTHSIMCSLFQ-CMLLUXCUSA-N 0.000 description 1
- HFTWTHSIMCSLFQ-UHFFFAOYSA-N Glabric acid Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)C(O)CC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C HFTWTHSIMCSLFQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- YYDLFVZOIDOGSO-KKBFJBPOSA-N Lycoricidine Chemical compound C1=C2C3=C[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=CC2=C1OCO2 YYDLFVZOIDOGSO-KKBFJBPOSA-N 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- LZAZURSABQIKGB-UHFFFAOYSA-N Narciclasine Tetraacetat Natural products C1=C2C3=CC(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 LZAZURSABQIKGB-UHFFFAOYSA-N 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000219998 Philenoptera violacea Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960001012 codeine hydrochloride Drugs 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- GBRZTUJCDFSIHM-UHFFFAOYSA-N licorisoflavan B Natural products C1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC1C1=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 비만 억제용 한약 조성물에 관한 것으로, 더욱 상세하게는 인체에 대한 부작용이 전혀 없이도 체중을 효과적으로 감소시켜 과체중이나 비만에 의해 유래되는 각종 질병이 예방될 수 있도록 한 비만 억제용 한약 조성물에 관한 것이다.The present invention relates to a Chinese herbal composition for inhibiting obesity, and more particularly, to a Chinese herbal composition for inhibiting obesity so that various diseases caused by overweight or obesity can be prevented by effectively reducing weight without any side effects on the human body. will be.
현대인의 대표적인 성인병의 근원은 비만에서 유래된다. 비만은 저장지방조직의 양이 비정상적으로 증가한 상태를 말하는 것으로서, 일반적으로 비만이라고 하면 체중의 30% 이상을 지방이 차지하고 있을 때를 말한다.The origin of the representative adult diseases of modern people is derived from obesity. Obesity refers to a state in which the amount of stored fat tissue is abnormally increased. In general, obesity refers to when the fat occupies more than 30% of the body weight.
비만의 원인으로는 유전적인 요인, 불규칙한 식습관이나 운동부족 또는 패스트푸드의 과다섭취 등에 의한 환경적인 요인, 우울증, 과도한 스트레스 등에 의한 심리적 요인, 갑상선이나 부신피질 호르몬 변화에 의한 호르몬 요인 등을 들 수 있다.The causes of obesity include genetic factors, environmental factors such as irregular eating habits or lack of exercise or excessive consumption of fast foods, psychological factors such as depression, excessive stress, and hormonal factors caused by thyroid or adrenocortical hormone changes .
비만은 섭취하는 열량이 소비하는 열량보다 많아 체내에 불필요한 지방의 축적이 일어나 발생하게 되는 것이므로, 비만을 해결하기 위하여서는 체내의 지방축적을 감소시키거나 또는 축적되어 있는 지방을 에너지원으로 사용하여 소모시켜야 하는 것이다.Obesity is more than the amount of calories consumed by the amount of calories consumed, so that unnecessary fat accumulation occurs in the body. Therefore, in order to solve the obesity, the fat accumulation in the body is reduced or the accumulated fat is used as the energy source and consumed .
한편, 체내에 지방이 축적되면 원활한 몸의 신진대사가 방해되고 내장의 기능이 저하됨에 따라 예를 들어 당뇨병, 고혈압, 동맥경화, 고지혈증, 심혈관질환, 지방간 등과 같은 성인병과 대사이상과 같은 질병을 발생시키는 근본 원인이 된다.On the other hand, when fat accumulates in the body, smooth metabolism of the body is disturbed and the functions of the internal organs are lowered. Thus, diseases such as diabetes, hypertension, arteriosclerosis, hyperlipemia, cardiovascular diseases, It becomes the root cause.
체내에 지방이 상당히 축적된 후에는 식이요법을 통한 다이어트와 운동을 병행하더라도 살이 잘 빠지지 않게 되는데, 이는 몸의 신진 대사기능이 극도로 저하되어 있어, 평소와 같은 양의 음식물을 섭취하여도 일반인보다 훨씬 지방이 몸에 축적되기 쉬운 상태로 되어 있기 때문이다.After a considerable accumulation of fat in the body, dieting and exercising together with the diet do not fall well, because the metabolism of the body is extremely low, so the usual amount of food, even if the general public This is because the fat is easily accumulated in the body.
몸의 신진대사 기능이 현저하게 떨어져 있는 상태에서 과도한 식이요법, 무리한 운동, 무분별한 약물을 남용할 경우에는 약간의 체중 감소를 기대할 수는 있으나, 극한의 공복감, 무력감, 어지러움증 등의 부작용을 유발할 수 있게 된다. 또한, 단순히 식사량을 줄이는 방법만으로 체중을 감소시키는 경우에는 요요현상으로 인하여 이전보다 체중이 더욱 많이 나가게 되는 폐해를 수반된다.Excessive dieting, excess exercise, and abuse of medically underexposed drugs can be expected to cause some weight loss, but can cause side effects such as extreme hunger, helplessness, and dizziness. do. In addition, in the case of simply reducing the weight by the method of reducing the amount of food, it is accompanied by a worse case that the weight is more increased than before due to the yo-yo phenomenon.
따라서, 최근에는 식이요법 후의 요요현상, 무리한 다이어트로부터 오는 과도한 스트레스, 다이어트 중의 공복감 내지 무력감 등의 문제점을 동시에 해결하기 위하여, 체내의 균형을 유지시키면서도 체내에 축적된 지방을 감소시키는 한방 다이어트 요법이 각광을 받고 있다.Therefore, recently, in order to solve the problems such as yo-yo phenomenon after the diet, excessive stress from the excessive diet, hunger feeling in the diet or powerlessness, the herbal diet therapy which reduces the accumulated fat in the body while maintaining the balance in the body, .
이러한 한방 다이어트 요법으로, 대장의 연동능력을 회복하고 숙변에서 발생하는 독소를 제거하기 위한 장세척 요법, 몸속의 365개에 달하는 경혈에 자극을 주는 체침 요법, 극소량의 정제된 한약재를 주입하는 약침 요법, 피부에 직접 음압을 가하는 부항 요법, 식욕을 억제하는 효과가 있는 귀에 맞는 이침 요법, 약쑥을 태워 온열자극 및 원적외선 자극을 통해 경락을 통하게 하고 원기를 돋아주는 뜸 요법, 피하지방에 직접 침을 꽂은 후 전기자극을 통해 지방을 분해하는 지방 분해 침 요법 등이 시행되고 있지만, 전술한 한방요법 중 어느 하나의 방법만으로는 극대의 효과를 기대할 수는 없어 여러 가지의 방법을 혼용하여 사용하고 있는 실정이다.These herbal dieting therapies include intestinal lavage therapy to restore the ability of the large intestine to recover the peristalsis of the large intestines, curettage therapy to stimulate the body's 365 acupuncture points, herbal remedy to infuse a very small amount of refined herbal medicine , Spontaneous treatment by applying direct negative pressure to the skin, incision therapy for the ear with the effect of suppressing the appetite, moxibustion by burning the wormwood, moxibustion through the meridian through the meridian and stimulation of the far infrared ray, And fat decomposition and acupuncture which dissolves fat through post-electrical stimulation are performed. However, any one of the herbal remedies described above can not be expected to have the greatest effect, and various methods are used in combination.
본 발명의 목적은 인체에 대한 부작용이 전혀 없이도 체중을 효과적으로 감소시켜 과체중이나 비만에 의해 유래되는 각종 질병이 예방될 수 있도록 한 비만 억제용 한약 조성물을 제공하는 것이다.An object of the present invention is to provide an herbal composition for inhibiting obesity to effectively reduce the weight without any side effects on the human body to prevent various diseases caused by overweight or obesity.
전술한 본 발명의 목적은, 마황, 창출, 의이인, 숙지황, 산사, 옥발, 송엽, 용안육 및 백복령을 포함하는 것을 특징으로 하는 비만 억제용 한약 조성물을 제공함에 의해 달성된다.The object of the present invention described above is achieved by providing an herbal composition for inhibiting obesity, which comprises ephedra, creation, Euiin, sujijihwang, hawthorn, oval, pine needles, longan meat and Baekbokyeong.
본 발명의 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 마황 20 내지 40 중량부, 창출 20 내지 40 중량부, 의이인 20 내지 40 중량부, 숙지황 10 내지 20 중량부, 산사 10 내지 20 중량부, 옥발 10 내지 20 중량부, 송엽 10 내지 20 중량부, 용안육 12 내지 28 중량부 및 백복령 10 내지 20 중량부를 포함하는 것이 바람직하다.According to a preferred feature of the invention, the herbal composition for inhibiting obesity, 20 to 40 parts by weight of ephedra, 20 to 40 parts by weight, 20 to 40 parts by weight of Euiyi, 10 to 20 parts by weight of sucrose sulfur, 10 to 20 parts by weight of hawthorn , 10 to 20 parts by weight of oxalate, 10 to 20 parts by weight of pine needles, 12 to 28 parts by weight of dragon meat and preferably 10 to 20 parts by weight of Baekbokyeong.
본 발명의 더 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 마황 30 중량부, 창출 30 중량부, 의이인 30 중량부, 숙지황 30 중량부, 산사 15 중량부, 옥발 15 중량부, 송엽 15 중량부, 용안육 20 중량부, 백복령 15 중량부를 포함를 포함한다.According to a more preferred feature of the present invention, the herbal composition for inhibiting obesity is 30 parts by weight of ephedra, 30 parts by weight, Euiin 30 parts by weight, 30 parts by weight of sucrose sulfur, 15 parts by weight of hawthorn, 15 parts by weight of oxybal, 15 weight of pine needles Part, including 20 parts by weight of longan meat, 15 parts by weight of Baekbokyeong.
본 발명의 더 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 마황 3g, 창출 3g, 의이인 3g, 숙지황 1.5g, 산사 1.5g, 옥발 1.5g, 송엽 1.5g, 용안육 2g, 백복령 1.5g이 1첩으로 처방되고 1일 2첩씩 물로 다려 복용된다.According to a more preferred feature of the present invention, the herbal composition for inhibiting obesity is ephedra, 3g, 3g, Euiyiin 3g, Sukji sulfur 1.5g, hawthorn 1.5g, octane 1.5g, pine needles 1.5g, longan meat 2g, Baekbokyeong 1.5g is 1 It is prescribed as a concubine and is infused with water twice a day.
본 발명의 더 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 마황 180g, 창출 180g, 의이인 180g, 숙지황 90g, 산사 90g, 옥발 90g, 송엽 90g, 용안육 120g, 백복령 90g을 물로 다려 1포당 100 내지 120cc로 90포로 제조한 후 1일 3포씩 복용된다.According to a more preferred feature of the present invention, the herbal composition for inhibiting obesity, ephedra 180g, 180g creation, 180g Euiin 180g, Sukjihwang 90g, hawthorn 90g, octane 90g, pine needles 90g, longan meat 120g, Baekbokyeong 90g per 100 to 1 bag Prepare 120 capsules at 120cc and take 3 capsules daily.
본 발명의 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 방기, 진피, 우슬, 당귀, 천궁, 소목, 애엽, 홍화자, 오가피, 황기 및 감초를 더 포함한다.According to a preferred feature of the present invention, the herbal composition for inhibiting obesity further includes anti-defense, dermis, dew, donkey, celestial organ, joiner, leafy, safflower, staphylococcus, astragalus and licorice.
본 발명의 더 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 방기 20 내지 40 중량부, 진피 12 내지 28 중량부, 우슬 10 내지 20 중량부, 당귀 10 내지 20 중량부, 천궁 10 내지 20 중량부, 소목 10 내지 20 중량부, 애엽 10 내지 20 중량부, 홍화자 10 내지 20 중량부, 오가피 10 내지 20 중량부, 황기 10 내지 20 중량부 및 감초 6 내지 14 중량부를 더 포함한다.According to a more preferred feature of the present invention, the herbal composition for inhibiting obesity, 20 to 40 parts by weight, dermis 12 to 28 parts by weight, 10 to 20 parts by weight of dew, 10 to 20 parts by weight, Angelica 10 to 20 parts by weight 10 parts by weight, 10-20 parts by weight, 10-20 parts by weight of young leaves, 10-20 parts by weight of safflower, 10-20 parts by weight, 10-20 parts by weight of astragalus, and 6-14 parts by weight of licorice.
본 발명의 더 바람직한 특징에 따르면, 상기 비만 억제용 한약 조성물은, 방기 30 중량부, 진피 20 중량부, 우슬 15 중량부, 당귀 15 중량부, 천궁 15 중량부, 소목 15 중량부, 애엽 15 중량부, 홍화자 15 중량부, 오가피 15 중량부, 황기 15 중량부 및 감초 10 중량부를 더 포함한다.According to a more preferable feature of the present invention, the herbal composition for inhibiting obesity, 30 parts by weight, dermis 20 parts by weight, 15 parts by weight of dew, 15 parts by weight of Angelica, 15 parts by weight, 15 parts by weight of saplings, 15 parts by weight of young leaves 15 parts by weight of safflower, 15 parts by weight of organo, 15 parts by weight of astragalus, and 10 parts by weight of licorice.
본 발명에 따른 비만 억제용 한약 조성물에 의하면, 인체에 대한 부작용이 전혀 없이도 체중을 효과적으로 감소시켜 과체중이나 비만에 의해 유래되는 각종 질병이 예방될 수 있는 탁월한 효과가 있다.According to the herbal composition for inhibiting obesity according to the present invention, by effectively reducing the weight without any side effects on the human body has an excellent effect that can prevent various diseases caused by overweight or obesity.
이하에는, 본 발명의 바람직한 실시예를 첨부도면을 참조하여 상세하게 설명하되, 이는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 발명을 용이하게 실시할 수 있을 정도로 상세하게 설명하기 위한 것이지, 이로 인해 본 발명의 기술적인 사상 및 범주가 한정되는 것을 의미하지는 않는다.
Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings, which are intended to describe in detail enough to be easily carried out by those skilled in the art to which the present invention pertains. This does not mean that the technical spirit and scope of the present invention is limited.
전술한 본 발명에 따른 비만 억제용 한약 조성물은, 마황, 창출, 의이인, 숙지황, 산사, 옥발, 송엽, 용안육 및 백복령을 포함한다.The above-described herbal composition for inhibiting obesity according to the present invention, ephedra, creation, Euiin, Sukjihwang, hawthorn, octave, pine needles, longan meat and Baekbokyeong.
여기서 마황(麻黃)은 마황속(Ephedra)의 식물의 총칭으로 예로부터 한약재로 널리 사용되었다. 마황에는 알칼로이드의 에페드린과 메틸에페드린이 함유되어, 부신수질호르몬의 아드레날린 작용과 유사하게 교감신경의 말단부를 자극하는 작용을 한다. 또한 마황은 열대사 촉진과 함께 식욕부진을 유발하여 비만치료에 사용되기도 한다. 마황에는 리성분으로 알칼로이드를 다량 함유하고 있는데, 주성분은 엘-에페드린(L-ephedrine)과 디-슈도에페드린(D-pseudoephedrine)으로, 인체의 소장에서 콜레스테롤 흡수를 저해하며, 지방조직에서 에너지 소비를 증가시켜 체지방분해 속도를 가속화시키는 역할을 한다. 마황은 부교감신경의 과다흥분으로 불면증을 초래하거나 혀의 마비와 같은 부작용도 초래하므로, 적정양만 사용하는 것이 바람직하다Here, mahwang (黄黄) is a generic term for Ephedra plants and has been widely used as herbal medicine since ancient times. Mahwah contains the alkaloids ephedrine and methyl ephedrine, which acts to stimulate the end of sympathetic nerves similar to the adrenergic action of the adrenal gland hormone. In addition, it promotes heat metabolism and induces anorexia and is used for the treatment of obesity. The main ingredient of L-ephedrine and D-pseudoephedrine is that it inhibits the absorption of cholesterol in the small intestine of the body and increases energy consumption in fat tissue. Thereby accelerating the decomposition rate of body fat. It is desirable to use only the appropriate amount, because it causes insomnia due to excessive excitement of the parasympathetic nerve or side effects such as paralysis of the tongue
마황은 20 내지 40 중량부, 특히 30 중량부의 비율로 사용되는 것이 바람직하다.It is preferable that mahwah is used in a proportion of 20 to 40 parts by weight, particularly 30 parts by weight.
창출은 국화과 여러해살이 풀인 삽주의 뿌리로, 발한, 이뇨, 진통 및 건위 등에 효능이 있어 위장염 및 감기 등에 효과가 있으며, 특히 중추신경 흥분을 억제와 진정작용의 역할을 하고 비만에 탁월한 효과가 있다. 창출은 주요 약리성분으로는 아트락티론(Atractylone), 아트락티롤(Atractylol) 및 비타민 A, D 등을 함유하고 있다.It is effective for sweating, diuretic, analgesic and dryness, and is effective for gastroenteritis and cold. Especially, it plays a role of suppressing and stimulating central nervous excitement and has an excellent effect on obesity. Its major pharmacological ingredients include attractylone, attractol, and vitamins A and D.
창출은 20 내지 40 중량부, 특히 30 중량부의 비율로 사용되는 것이 바람직하다.It is preferable to use 20 to 40 parts by weight, especially 30 parts by weight, of the composition.
의이인은 율무라고도 하며 벼과의 한해살이 풀을 말하는 것으로, 포만감을 유지하며 몸 안의 지방질 분해를 돕는 역할을 하며 항염작용과 콜리스테롤의 함량을 낮춰주는 역할을 한다. 의이인은 쌀에 비해 칼로리가 낮으며 공복시에 허기를 감소시켜 식욕을 줄이는 효과가 있고 불필요한 수분을 배출시켜 다이어트 효과를 가져오는 작용을 하는 것으로 알려져 있다Uiin is also known as yulmu and refers to the annual plant of the rice paddy, maintains the satiety feeling, helps to break down the fat in the body, anti-inflammatory action and lowers the content of cholesterol. Uiin has a lower calorie than rice and has the effect of reducing appetite by reducing hunger on fasting, and it is known that it acts to bring about diet effect by discharging unnecessary water
의이인은 20 내지 40 중량부, 특히 30 중량부의 비율로 사용되는 것이 바람직하다.It is preferable to use 20 to 40 parts by weight, especially 30 parts by weight, of phosphorus.
숙지황은 지황(地黃)의 뿌리를 쪄서 말린 한약재로서, 식사량을 줄였을 경우 공복감을 덜어줌과 동시에 숙변을 제거하여 장운동을 활성화시키며, 보혈, 정혈작용이 우수한 것으로 알려져 있다.Sukjihwang is a Chinese herb medicine which is steamed and dried by the roots of Zhiwang (地黄). It is known that when the amount of food is reduced, it hampers the hunger and activates the intestinal tract by removing the sukbyeon.
숙지황은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferable that the hydrolyzate is used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
산사는 장미과의 산사나무(Crataegus pinnatifida Bunge var. typica Schneider) 및 동속식물의 익은 열매를 말린 약재를 말하는 것으로, 비위를 따뜻하게 하여 소화를 촉진하며 고기를 먹고 체했을 때 효과가 있고 복통, 구토, 설사, 위산과다, 만성장염 등에 처방된다. 또한 산사는 혈분에 작용하여 혈의 흐름을 돕고 어혈을 없애주며, 약리작용으로 강심작용, 혈액순환개선 작용, 혈압강하작용이 있는 것으로 알려져 있다. 특히 산사는 시트릭산과 탄닌, 퀘르세틴이 다량 함유되어 있어 혈전을 제거하고 콜레스테롤을 낮추는 작용을 한다. Crataegus pinnatifida Bunge var. Typica Schneider is a medicinal herb that is used to dry ripe berries of rosacea. It promotes digestion by warming the nausea and is effective when it eats meat. It is effective for abdominal pain, vomiting, diarrhea , Gastric hyperplasia, chronic enteritis, etc. are prescribed. In addition, Sansa acts on the blood stream to help the flow of blood, eliminates the eosinophilia, and is known to have pharmacological actions such as arteriosclerosis, blood circulation improvement, and hypotensive effect. Especially, it has a high content of citric acid, tannin and quercetin, which removes thrombus and lowers cholesterol.
산사는 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferable that the acid value is used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
옥발은 옥수수수염을 말하는 것으로, 이뇨작용이 탁월하여 체내 노폐물을 배출시켜 체중감량에 탁월한 작용을 한다. 또한 옥발은 담즙분비를 촉진시키고 혈압과 혈당을 내리며 지혈작용을 하는 것으로 알려져 있다.Oval refers to corn beard, which is excellent in diuretic action to waste the body to exert an excellent effect in weight loss. Also, it is known that oxvalue promotes bile secretion, lowering blood pressure and blood sugar, and performing a hemostatic function.
옥발은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferred that the content of oxal is used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
송엽은 통상 솔잎을 말하는 것으로, 지방 합성을 저해하고, 체중을 감소시키는 효과가 있다. 송엽에는 테르펜, 페놀화합물, 탄닌 등의 정유성분과 엽록소, 무기 및 유기성분, 비타민류 등 다양한 성분이 함유되어 있다. 이 중 테르펜은 콜레스테롤 축적을 막고, 말초혈관을 확장시켜 혈액 순환을 촉진하는 효과가 있다.Pine bark usually refers to pine needles, which inhibits fat synthesis and has the effect of reducing body weight. Pine needles contain terpenes, phenolic compounds, tannins and other essential oils, chlorophyll, inorganic and organic components, and vitamins. Among these, terpene is effective in preventing cholesterol accumulation and promoting blood circulation by expanding peripheral blood vessels.
송엽은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.The pine bark is preferably used in a proportion of 10 to 20 parts by weight, especially 15 parts by weight.
용안육은 무환자나무과의 용안(Dimocarpus longan Lour.:龍眼)의 가종피를 말하는 것으로, 강장작용, 항산화작용, 면역 기능활성화작용이 우수한 것으로 알려져 있다. 또한 용안육은 육혈을 보하고 정신안정효과가 있어 숙면을 유도하며, 뇌를 튼튼하게 하고 심장과 비장을 보호하는 데 효과적이다.It is known that the dragon grass (Dimocarpus longan Lour .: dragon eye) is the seed coat of the dragon eye, and it is known that it has excellent tonic action, antioxidant activity and immune function activating action. In addition, Yonggan meat has a blood-tightening effect and a mental stabilizing effect, inducing a good sleep, strengthening the brain, and protecting the heart and spleen.
용안육은 12 내지 28 중량부, 특히 20 중량부의 비율로 사용되는 것이 바람직하다.The yogurt is preferably used in a proportion of 12 to 28 parts by weight, especially 20 parts by weight.
백복령은 복령(Poria cocas Wolf.)의 균핵을 말린 것을 말하는 것으로, 예로부터 강장제로 사용되었다. 백복령은 폐경(肺經), 비경(脾經), 심경(心經), 신경(腎經), 방광경(膀胱經)에 작용하여 비장을 보하고 가래를 삭이며 정신을 안정시킨다. 약리실험 결과에 의하면 이뇨작용과 혈당량을 낮추는 작용, 진정작용 등을 하는 것으로 밝혀졌으며 면역 부활작용을 하는 것으로도 알려져 있다.Baek Bok-ryeong refers to dried sclerot of Poria cocas Wolf. It has been used as a tonic for a long time. Baekbok-ri acts on menopause (肺 经), necrosis (脾 经), heart (经经), nerves (肾 经) and bladder (膀 经) to see the spleen, sputum and mental stability. Pharmacological studies have shown that diuretic action, lowering of blood sugar level, sedation, etc. It is also known that the immune revival function.
백복령은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferable that the baechlabyeong is used in a ratio of 10 to 20 parts by weight, particularly 15 parts by weight.
전술한 비만 억제용 한약 조성물은, 마황 3g, 창출 3g, 의이인 3g, 숙지황 1.5g, 산사 1.5g, 옥발 1.5g, 송엽 1.5g, 용안육 2g, 백복령 1.5g이 1첩으로 처방되고 1일 2첩씩 물로 다려 복용된다. 이 경우 마황은 1일 6g을 복용하게 되는데, 1일 허용치인 18g보다 훨씬 적은 양으로도 비만억제에 탁월한 효과를 볼 수 있다.The above-described herbal composition for inhibiting obesity is ephedra 3g, 3g creation, 3g Euiin 3g, Sukji sulfur 1.5g, hawthorn 1.5g, octane 1.5g, pine needles 1.5g, yongan 2g, Baekbokryeong 1.5g is prescribed in one lap and two laps per day Take with water. In this case, Ma Zhang will take 6g a day, much less than the daily allowance of 18g, can be effective in suppressing obesity.
또한 전술한 비만 억제용 한약 조성물은, 마황 180g, 창출 180g, 의이인 180g, 숙지황 90g, 산사 90g, 옥발 90g, 송엽 90g, 용안육 120g, 백복령 90g을 물로 다려 1포당 100 내지 120cc로 90포로 제조한 후 1일 3포씩 복용된다. 이 경우도 마황은 1일 6g을 복용하게 되는데, 1일 허용치인 18g보다 훨씬 적은 양으로도 비만억제에 탁월한 효과를 볼 수 있다.In addition, the above-described anti-obesity herbal composition is ephedra 180g, 180g creation, 180g Euiin 180g, Sukjihwang 90g, hawthorn 90g, 90g octopus, pine needles 90g, 120g of yongryok, 90g of Baekbokyeong with 100 to 120cc per bag and then prepared in 90 bags Take 3 sachets daily. In this case, too, 6mg a day will take the day, but much less than the daily allowance of 18g can be seen in the effect of suppressing obesity.
또한 본 발명에 따른 비만 억제용 한약 조성물은, 전술한 마황, 창출, 의이인, 숙지황, 산사, 옥발, 송엽, 용안육 및 백복령 외에 방기, 진피, 우슬, 당귀, 천궁, 소목, 애엽, 홍화자, 오가피, 황기 및 감초를 더 포함하는 것이 바람직하다.In addition, the herbal composition for inhibiting obesity according to the present invention, in addition to the above-mentioned ephedra, creation, Euiin, Sukjihwang, hawthorn, octave, pine needles, longan meat and Baekbokryeong, Banggi, dermis, dew, mule, cheongung, joiner, love leaf, safflower, Ogapi, It is preferable to further include Astragalus and licorice.
여기서, 방기는 방기과의 방기(Sinomenium acutum (Thunb.) Rehder& E.H.Wilson)의 덩굴성줄기 및 뿌리줄기를 사용해 만든 약재로 진통작용, 소염작용, 해열작용, 횡문근 이완작용, 기관지 평활근이완작용, 항균, 항종양작용이 탁월한 것으로 알려져 있다. 방기는 비만 억제효과도 탁월하여 비만치료에 있어 방기황기탕의 형태로 많이 처방되고 있다.Herein, Bunggi is a medicinal substance made from the vine stalks and rootstocks of Sinomenium acutum (Thunb.) Rehder & EHWilson. It has analgesic action, anti-inflammatory action, antipyretic action, rhabdoid relaxation action, bronchial smooth muscle relaxation action, The antitumor action is known to be excellent. Bugi is also excellent in the effect of suppressing obesity, so it is prescribed in the form of Bangui Hwanggi - tang in the treatment of obesity.
방기는 20 내지 40 중량부, 특히 30 중량부의 비율로 사용되는 것이 바람직하다.The emulsion is preferably used in a proportion of 20 to 40 parts by weight, particularly 30 parts by weight.
진피는 운향과의 귤(Citrus unshiu Markovich) 또는 동속 근연식물의 성숙한 과피를 말하는 것으로, 기가 뭉친 것을 풀어주고 비장의 기능을 강화하여 복부창만, 트림, 구토, 메스꺼움, 소화불량, 헛배가 부르고 나른한 증상, 대변이 묽은 증상을 치료하며, 해수, 가래를 없애주며 이뇨작용을 한다. 또한 진피는 정유 성분이 다량 함유되어 소화기자극, 소화촉진, 거담, 항궤양, 항위액분비, 강심, 혈압상승, 항알레르기, 담즙분비촉진, 자궁평활근억제, 항균작용 등의 약리작용이 우수한 것으로 알려져 있다. 진피는 기순환을 향상시켜 신진대사를 촉진시킴에 따라 비만 억제에 효과를 나타내고 헤스페레틴이 함유되어 콜레스테롤을 낮춰주는 역할을 한다.The dermis is the mature peri of the citrus unshiu Markovich or the relative plant of the same species, and it releases the giggles and strengthens the function of the spleen, so that the abdominal cavity, trimming, vomiting, nausea, indigestion, , Treats the dilute symptoms of stool, eliminates seawater, sputum and diuretic action. Dermis is also known to have excellent pharmacological effects such as digestive stimulation, digestive stimulation, germane, anti-ulcer, antidiarrheal secretion, hypertension, elevated blood pressure, antiallergic activity, bile secretion promotion, uterine smooth muscle suppression, have. The dermis enhances circulation and promotes metabolism, thereby reducing obesity and lowering cholesterol by the inclusion of hesperetin.
진피는 12 내지 28 중량부, 특히 20 중양부의 비율로 사용되는 것이 바람직하다.The dermis is preferably used in a proportion of 12 to 28 parts by weight, particularly 20 parts by weight.
우슬은 비름과의 쇠무릎(Achyranthes japonica Nakai) 또는 우슬(Acyranthes bidentata Blume:牛膝)의 뿌리를 말하는 것으로, 어혈과 종기를 없애고, 간과 신장을 보해 근육, 골격을 튼튼하게 하며, 어혈을 제거해 줌으로써 생리불순, 산후복통에도 효과적이며, 골수를 보충하고 음기를 잘 통하게 한다. 우슬은 자궁흥분작용, 콜레스테롤 강하작용, 이뇨작용, 혈당강하작용, 간기능 개선작용과 같은 약리작용이 우수한 것으로 알려져 있다. 우슬은 특히 혈행을 개선하고 콜레스테롤을 강하시며 비만치료에 우수한 효과가 있다.It is the roots of Achyranthes japonica Nakai or Acyranthes bidentata Blume (牛 膝). It removes eosinophilia and boils, strengthens the muscles and skeleton by observing liver and kidneys, It is also effective in impoverishment, postpartum abdominal pain, and it replenishes the bone marrow and makes it easy to drink. It has been known to have excellent pharmacological effects such as uterine stimulation, cholesterol lowering, diuretic action, hypoglycemic action, and liver function improvement. It is especially effective in improving blood circulation, strengthening cholesterol and treating obesity.
우슬은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.The mist is preferably used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
당귀는 산형과에 속하는 참당귀의 뿌리를 건조시킨 약재로, 방향성 정유와 비타민 E 등이 함유되어 있다. 당귀는 혈액순환을 촉진시키고 진통효과를 나타내며, 보혈작용이 현저하여 빈혈에 유효하고 일반 타박상이나 혈전성동맥염의 치료에도 응용된다. 또한 당귀는 혈액순환을 개선시키고 체내의 저항력을 증강시키며, 변비에 복용하면 장관운동을 원활하게 해주어 배변을 용이하게 함으로써 비만에 효과도 있다.Angelica is a medicinal herb that has dried the roots of Angelica angustifolia (Angelica gigas) belonging to the Acanthopanax family. It contains aromatic essential oil and vitamin E. The Angelica gigas promote blood circulation, exhibit analgesic effects, are prominent in the blood, and are effective for anemia and are also used for the treatment of general bruising and thrombotic arteritis. It also improves blood circulation and strengthens the resistance of the body. When taken in constipation, it stimulates bowel movements and facilitates bowel movements.
당귀는 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferable that Angelicae is used in a ratio of 10 to 20 parts by weight, particularly 15 parts by weight.
천궁은 쌍떡잎식물 이판화군 산형화목 미나리과의 여러해살이풀의 뿌리줄기를 건조시킨 것을 말하는 것으로, 방향성정유를 다량 함유하고 있다. 천궁은 주성분으로 크니딜라이드(cnidilide), 네오크니딜라이드(neocnidilide), 리구스틸라이드(ligustilide) 등을 포함하에 따라, 중추신경계통에 작용하여 진정효과가 있으며, 지속적인 혈압강하작용도 나타낸다. 천궁은 특히 체내에서 혈액순환을 왕성하게 촉진시켜 미만치료에 효과적이며 통증을 가라앉히는 진통효과도 있고, 간장의 기능을 활성화시켜 주고 조혈작용에서도 탁월한 효과가 있다.It is a dried plant of perennial herbaceous perennial herbaceous perennial herbaceous plant, which contains a large amount of aromatic essential oil. Astragalus is a major component that acts on the central nervous system, including cnidilide, neocnidilide, and ligustilide, and has sedative effects and sustained hypotensive effects. It is especially effective in the treatment of under-treatment by accelerating the blood circulation in the body, and it has an analgesic effect that calms the pain, activates the function of the liver, and exerts an excellent effect in the hematopoietic action.
천궁은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferred that the cuneiform is used in a proportion of 10 to 20 parts by weight, especially 15 parts by weight.
소목은 소방목(蘇枋木), 적목(赤木), 홍자(紅紫)라고도 하며, 학명은 Caesalpinia sappan L.이다. 소목은 행혈(行血)·지혈·구어혈(驅瘀血)·진통·소종(消腫)의 효능이 있어 심재(心材)를 약재로 사용한다. 소목은 식욕을 줄여주고 지방을 분해하는 효과가 있어 비만치료에 탁월한 효과가 나타낸다.Callus is also called firewood, red-eyed tree, and red-purple, and its scientific name is Caesalpinia sappan L. The joan has the efficacy of blood-sucking, blood-sucking, gut-hemorrhaging, analgesic, and exenteration, and uses heartwood as a medicinal product. It has the effect of reducing appetite and decomposing fat, thus showing excellent effects in the treatment of obesity.
소목은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferable that the copper alloy be used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
애엽은 국화과의 황해쑥(Artemisia argyi Lev. et Vant.), 쑥(A. princeps Pamp. var. orientlis Hara) 또는 산쑥(A. montana Pamp.)의 잎 및 어린줄기를 말린 약재를 말하는 것으로, 기혈(氣血)과 경맥(經脈)을 따뜻하게 하므로 자궁과 하복부가 허약하고 차서 생기는 자궁 출혈, 임신 중 출혈, 토혈, 코피, 각혈에 지혈 반응을 나타내고, 하초(下焦)가 허약하고 차며 복부에 냉감과 동통이 있는 증상 및 생리불순, 생리통, 대하(帶下) 등에 사용하며 습진, 피부가려움증에도 효과가 있다. 애엽의 약리작용으로 지혈작용, 억균작용, 기관지 평활근 이완작용, 진해거담작용, 수면작용, 자궁흥분유도작용, 과민성 쇼크 보호작용 등이 있다. 애엽은 혈액순환을 완성하게 하여 노폐물배출을 촉진시켜 비만억제에 탁월한 효과가 있다.The leaf is a plant which dried leaves and young stems of Artemisia argyi Lev. Et Vant., A. princeps Pamp. Var. Orientlis Hara or A. montana Pamp. (气血) and gyeongmaek (经脉) to warm the uterus and lower abdomen, resulting in uterine bleeding, bleeding during pregnancy, hemorrhage, hemorrhage, nosebleeds, hemorrhagic reactions to the blood, It is used for painful symptoms, menstrual irritation, menstrual pain, subarachnoid, etc. It is also effective for eczema and skin itching. The pharmacological action of the epilepsy is hemostatic, bacillary, bronchial smooth muscle relaxation, intestinal genomic action, sleeping action, uterine excitation induction action, and hypersensitive shock protection action. The lobe perfuses the blood circulation, promotes the discharge of waste products, and has an excellent effect in suppressing obesity.
애엽은 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.It is preferred that the lashes are used in a proportion of 10 to 20 parts by weight, especially 15 parts by weight.
홍화자는 통상의 홍화씨를 말하는 것으로. 혈액을 잘 순환시켜 노폐물배출을 촉진시켜 비만을 억제시키며 해독(解毒)작용이 탁월한 있는 약재이다. 홍화자는 리놀렌산을 다량 함유하여 고혈압과 동맥경화에 탁월한 효과가 있으며 체내 지방을 분해하여 비만을 억제하는 탁월한 효과가 있다.Safflower refers to ordinary safflower seed. It circulates the blood well, promotes the discharge of waste products, inhibits obesity and detoxifies. The safflower contains a large amount of linolenic acid, which has excellent effects on hypertension and atherosclerosis, and has an excellent effect of decomposing body fat and inhibiting obesity.
홍화자는 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다.The safflower is preferably used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
오가피는 두릅나무과 오갈피나무 또는 동속식물의 껍질를 말린 약재를 말하는 것으로, 강장과 강심작용이 탁월한 것으로 알려져 있다.Ogapi is a medicinal plant that dried the shells of Araliaceae, Acanthopanax japonica, and Orangutan, and it is known to be excellent in strength and strength.
오가피는 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다. It is preferable that the organoleptic agent is used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
황기는 콩과에 속하는 다년생 초본식물로, 혈관을 확장시키고 지방분해를 촉진하는 작용이 있으며, 퀘르세틴이 다량 함유되어 콜레스테롤을 감소시키는 약리작용을 한다. Hwanggi is a perennial herbaceous plant belonging to soybean family. It has the function of expanding blood vessels and promoting fat decomposition. It contains a large amount of quercetin and acts as a pharmacological effect to reduce cholesterol.
황기는 10 내지 20 중량부, 특히 15 중량부의 비율로 사용되는 것이 바람직하다. It is preferable that the sulfur content is used in a proportion of 10 to 20 parts by weight, particularly 15 parts by weight.
감초는 콩과에 속하는 다년생 초본식물의 뿌리를 건조시킨 한약재로, 감미가 있는 글리시리진과 글라브릭산, 슈크로즈, 글루코즈, 리퀴리틴, 리코리시딘 등이 함유되어 있다. 글리시리진은 디프테리아 독소, 파상풍 독소, 염산 코데인, 초산 스트리키닌, 뱀독·복어독 등을 해독하는 작용이 있으며 항염증 작용이 있어 부종을 억제하는 효과도 있다. 또한 글리시리진은 혈액 중의 콜레스테롤치를 내려주어 혈압강하의 효과가 있으며, 담즙의 분비를 촉진시키고 진해작용, 진통작용이 있는 것으로 알려져 있다. 또한 감초는 궤양억제작용, 항암작용도 있는 것을 알려져 있으며 다른 약재들의 기능이 조화되도록 하며 특히 입맛을 떨어뜨리는 효과가 있는 것으로 알려져 있다.Licorice is a medicinal herb that has dried the roots of perennial herbaceous plants belonging to the legume, and contains sweetening glycyrrhizin, glabric acid, sucrose, glucose, liquiritin, lycoricidine and the like. Glycyrrhizin has the effect of detoxifying diphtheria toxin, tetanus toxin, codeine hydrochloride, strychnine acetate, snake venom and swine flu, and has an anti-inflammatory action, which also suppresses edema. Glycyrrhizin is also known to lower cholesterol levels in the blood, to lower blood pressure, to promote the secretion of bile, and to have vasodilatation and analgesic action. Licorice is also known for its anti-ulcer and anticancer properties, and is known to have the effect of harmonizing the functions of other medicines, especially the taste buds.
감초는 6 내지 14 중량부, 특히 10 중량부의 비율로 사용되는 것이 바람직하다.The licorice is preferably used in a proportion of 6 to 14 parts by weight, especially 10 parts by weight.
본 발명에 따른 비만 억제용 한약 조성물을 구성하는 각각의 성분들의 중량부 범위는 각 성분들의 효과와 부작용 가능성을 기준으로 한정된 것으로, 중량비 범위의 상한값은 부작용 및 다른 구성성분의 함량을 전체적으로 고려하여 결정되었고 중량비 범위의 하한값은 그 이하에서는 해당 구성성분의 효과가 떨어지는 문제가 있어, 상술한 바와 같은 수치범위로 한정됨을 밝혀 둔다.The weight range of each component constituting the herbal composition for inhibiting obesity according to the present invention is limited based on the effects of each component and the possibility of side effects, and the upper limit of the weight ratio range is determined in consideration of the side effects and the contents of other components as a whole. And the lower limit of the weight ratio range is less than that there is a problem that the effect of the component is falling, it is clear that it is limited to the numerical range as described above.
본 발명에 따른 비만 억제용 한약 조성물을 아래의 실시예 1 내지 6에 따라 제조하여 성인남녀 각각 10명에게 30일간 복용시킨 결과는 아래와 같다:Obesity inhibitory herbal composition according to the present invention was prepared according to Examples 1 to 6 below to take 10 adult men and women each 30 days as follows:
마황 3g, 창출 3g, 의이인 3g, 숙지황 1.5g, 산사 1.5g, 옥발 1.5g, 송엽 1.5g, 용안육 2g 및 백복령 1.5g을 1첩으로 포장하고 매일 하루 2첩씩 30일간 물로 다려 복용한 결과, 성인남자 10명의 경우 평균 4.5kg의 체중감량효과가 나타났고, 성인여자 10명의 경우 3.2kg의 체중감량효과가 나타났다.Ephedra 3g, Creation 3g, Euiin 3g, Sookjihwang 1.5g, Sansa 1.5g, Octal 1.5g, Pine needles 1.5g, Longan meat 2g and Baekbokryeong 1.5 grams packed in a pack of 1 day and ironed twice daily for 30 days, adult Ten males had an average weight loss of 4.5 kg, and ten female women had an average weight loss of 3.2 kg.
마황 3g, 창출 3g, 의이인 3g, 숙지황 1.5g, 산사 1.5g, 옥발 1.5g, 송엽 1.5g, 용안육 2g, 백복령 1.5g, 방기 3g , 진피 2g, 우슬 1.5g, 당귀 1.5g, 천궁 1.5g, 소목 1.5g, 애엽 1.5g, 홍화자 1.5g, 오가피1.5g , 황기 1.5g 및 감초 1g을 1첩으로 포장하고 매일 하루 2첩씩 30일간 물로 다려 복용한 결과, 성인남자 10명의 경우 평균 5.4kg의 체중감량효과가 나타났고, 성인여자 10명의 경우 3.8kg의 체중감량효과가 나타났다.Ephedra 3g, Creation 3g, Euiin 3g, Sukjihwang 1.5g, Sansa 1.5g, Octal 1.5g, Pine needles 1.5g, Longan meat 2g, Baekbokyeong 1.5g, Banggi 3g, Dermis 2g, Wavy 1.5g, Angelica 1.5g, Cheongung 1.5g, 1.5g, young leaf 1.5g, safflower 1.5g, Ogapi 1.5g, Astragalus 1.5g, and 1g licorice were packed in 1 pack and infused for 2 days a day with water for 30 days. The weight loss effect was shown, and 10 adult women showed weight loss effect of 3.8kg.
마황 180g, 창출 180g, 의이인 180g, 숙지황 90g, 산사 90g, 옥발 90g, 송엽 90g, 용안육 120g, 백복령 90g을 물로 다려 1포당 110cc로 90포로 제조한 후 1일 3포씩 복용한 결과, 성인남자 10명의 경우 평균 4.7kg의 체중감량효과가 나타났고, 성인여자 10명의 경우 3.5kg의 체중감량효과가 나타났다.Ephedra 180g, Creation 180g, Euiin 180g, Sukjihwang 90g, Sansa 90g, Octal 90g, Pine needles 90g, Longan meat 120g, Baekbokryeong 90g was prepared with 110cc per bag and then taken three bags a day, 10 adult men The average weight loss effect was 4.7kg, and 10 adult women showed weight loss effect of 3.5kg.
마황 180g, 창출 180g, 의이인 180g, 숙지황 90g, 산사 90g, 옥발 90g, 송엽 90g, 용안육 120g, 백복령 90g, 방기 180g , 진피 120g, 우슬 90g, 당귀 90g, 천궁 90g, 소목 90g, 애엽 90g, 홍화자 90g, 오가피 90g , 황기 90g 및 감초 60g을 물로 다려 1포당 110cc로 90포로 제조한 후 1일 3포씩 복용한 결과, 성인남자 10명의 경우 평균 5.1kg의 체중감량효과가 나타났고, 성인여자 10명의 경우 3.9kg의 체중감량효과가 나타났다.Ephedra 180g, Creation 180g, Euiin 180g, Sukjihwang 90g, Sansa 90g, Octal 90g, Pine needles 90g, Longan meat 120g, Baekbokyeong 90g, Banggi 180g, Dermis 120g, Woosel 90g, Angelica 90g, Cheongung 90g, Joiner 90g, Apple leaf 90g, Safflower 90g , 90g of Ogapi, 90g of Astragalus and 60g of licorice were prepared by filling 110cc per packet of 90cc and taking 3 capsules per day.The average weight loss effect was 5.1kg for 10 adult males and 10 adult females. A weight loss effect of 3.9 kg was shown.
Claims (8)
마황 20 내지 40 중량부, 창출 20 내지 40 중량부, 의이인 20 내지 40 중량부, 숙지황 10 내지 20 중량부, 산사 10 내지 20 중량부, 옥발 10 내지 20 중량부, 송엽 10 내지 20 중량부, 용안육 12 내지 28 중량부 및 백복령 10 내지 20 중량부를 포함하는 것을 특징으로 하는 비만 억제용 한약 조성물.The method according to claim 1,
Ephedra 20 to 40 parts by weight, 20 to 40 parts by weight, Euiin 20 to 40 parts by weight, 10 to 20 parts by weight of sucrose, 10 to 20 parts by weight of hawthorn, 10 to 20 parts by weight, 10 to 20 parts by weight of pine needles, dragon meat Chinese medicine composition for inhibiting obesity, comprising 12 to 28 parts by weight and 10 to 20 parts by weight of baekbokyeong.
마황 30 중량부, 창출 30 중량부, 의이인 30 중량부, 숙지황 30 중량부, 산사 15 중량부, 옥발 15 중량부, 송엽 15 중량부, 용안육 20 중량부, 백복령 15 중량부를 포함하는 것을 특징으로 하는 비만 억제용 한약 조성물.The method according to claim 2,
Ephedra 30 parts by weight, creation 30 parts by weight, Euiin 30 parts by weight, sukjihwang 30 parts by weight, 15 parts by weight of hawthorn, 15 parts by weight octane, pine leaves 15 parts by weight, longan meat 20 parts by weight, Baekbokyeong characterized in that it comprises 15 parts by weight Herbal composition for inhibiting obesity.
마황 3g, 창출 3g, 의이인 3g, 숙지황 1.5g, 산사 1.5g, 옥발 1.5g, 송엽 1.5g, 용안육 2g, 백복령 1.5g이 1첩으로 처방되고 1일 2첩씩 물로 다려 복용되는 것을 특징으로 하는 비만 억제용 한약 조성물.The method according to claim 3,
Ephedra 3g, 3g creation, 3g Euiin, 1.5g Sookjihwang 1.5g, hawthorn 1.5g, 1.5g octopus, pine needles 1.5g, longan meat 2g, 1.5g Baekbokyeong is prescribed as one lap and obesity characterized in that it is ingested with water twice a day Chinese herbal composition for inhibition.
마황 180g, 창출 180g, 의이인 180g, 숙지황 90g, 산사 90g, 옥발 90g, 송엽 90g, 용안육 120g, 백복령 90g을 물로 다려 1포당 100 내지 120cc로 90포로 제조한 후 1일 3포씩 복용하는 것을 특징으로 하는 특징으로 하는 비만 억제용 한약 조성물. The method according to claim 3,
Ephedra 180g, Creation 180g, Euiin 180g, Sukjihwang 90g, Sansa 90g, Octal 90g, Pine needles 90g, Longan meat 120g, Baekbokyeong 90g with water to prepare 100 to 120cc per 90 bags, characterized in that to take 3 bags per day Chinese herbal composition for inhibiting obesity.
방기, 진피, 우슬, 당귀, 천궁, 소목, 애엽, 홍화자, 오가피, 황기 및 감초를 더 포함하는 것을 특징으로 하는 한약재를 이용한 비만 억제용 조성물.The method according to any one of claims 1 to 5,
Anti-obesity, dermis, dew, donkey, cheongung, joiner, leaflet, safflower, scabies, astragalus and licorice composition for inhibiting obesity using a herbal medicine further comprising.
방기 20 내지 40 중량부, 진피 12 내지 28 중량부, 우슬 10 내지 20 중량부, 당귀 10 내지 20 중량부, 천궁 10 내지 20 중량부, 소목 10 내지 20 중량부, 애엽 10 내지 20 중량부, 홍화자 10 내지 20 중량부, 오가피 10 내지 20 중량부, 황기 10 내지 20 중량부 및 감초 6 내지 14 중량부를 더 포함하는 것을 특징으로 하는 한약재를 이용한 비만 억제용 조성물.The method of claim 6,
Banggi 20-40 parts by weight, dermis 12-28 parts by weight, 10-20 parts by weight of dew, 10-20 parts by weight of Angelica, 10-20 parts by weight of bowels, 10-20 parts by weight of lumber, 10-20 parts by weight of young leaves, safflower 10 to 20 parts by weight, Ogapi 10 to 20 parts by weight, Astragalus 10 to 20 parts by weight and 6 to 14 parts by weight licorice further comprises a composition for inhibiting obesity using a herbal medicine.
방기 30 중량부, 진피 20 중량부, 우슬 15 중량부, 당귀 15 중량부, 천궁 15 중량부, 소목 15 중량부, 애엽 15 중량부, 홍화자 15 중량부, 오가피 15 중량부, 황기 15 중량부 및 감초 10 중량부를 더 포함하는 것을 특징으로 하는 한약재를 이용한 비만 억제용 조성물.The method of claim 7,
30 parts by weight, 20 parts by weight of dermis, 15 parts by weight of dew, 15 parts by weight of Angelica, 15 parts by weight of bowels, 15 parts by weight of young leaves, 15 parts by weight of safflower, 15 parts by weight of safflower, 15 parts by weight of astragalus and A composition for inhibiting obesity using a herbal medicine, characterized in that it further comprises 10 parts by weight licorice.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120050479A KR101466862B1 (en) | 2012-05-11 | 2012-05-11 | Compositions for reducing weight |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120050479A KR101466862B1 (en) | 2012-05-11 | 2012-05-11 | Compositions for reducing weight |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130126380A true KR20130126380A (en) | 2013-11-20 |
KR101466862B1 KR101466862B1 (en) | 2014-12-03 |
Family
ID=49854491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120050479A KR101466862B1 (en) | 2012-05-11 | 2012-05-11 | Compositions for reducing weight |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101466862B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101888471B1 (en) * | 2018-02-23 | 2018-08-14 | 주식회사 위드내추럴 | Compostions for reducing weight using herb medicine |
KR101888475B1 (en) * | 2018-02-23 | 2018-08-14 | 주식회사 위드내추럴 | Compostions for reducing weight using herb medicine |
WO2019107638A1 (en) * | 2017-11-29 | 2019-06-06 | 극동대학교 산학협력단 | Jelly made of traditional herbal medicines for preventing obesity and preparation method therefor |
WO2019132416A1 (en) * | 2017-12-29 | 2019-07-04 | 주식회사 누베베 | Method for producing herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
WO2019132417A1 (en) * | 2017-12-29 | 2019-07-04 | 주식회사 누베베 | Herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
KR20190082075A (en) * | 2017-12-29 | 2019-07-09 | 주식회사 누베베 | Method for manufacturing a herbal medicine tablet for using a weight loss agent |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109123632A (en) * | 2018-08-30 | 2019-01-04 | 衡先培 | Prevent and treat food complex and its production of fat, fatty liver and rear hair disease |
KR20230020333A (en) | 2021-08-02 | 2023-02-10 | 유영재 | Composition of health functional food for improvement of obesity and blood circulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100510239B1 (en) * | 2005-07-26 | 2005-08-29 | (주)엔돌핀에프앤비 | Method for preparing a composition containing corn silk and dietary fibre |
-
2012
- 2012-05-11 KR KR1020120050479A patent/KR101466862B1/en active IP Right Grant
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019107638A1 (en) * | 2017-11-29 | 2019-06-06 | 극동대학교 산학협력단 | Jelly made of traditional herbal medicines for preventing obesity and preparation method therefor |
KR101969236B1 (en) * | 2017-11-29 | 2019-07-22 | 극동대학교 산학협력단 | Oriental Medicine Jelly and Producing Method Thereof |
WO2019132416A1 (en) * | 2017-12-29 | 2019-07-04 | 주식회사 누베베 | Method for producing herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
WO2019132417A1 (en) * | 2017-12-29 | 2019-07-04 | 주식회사 누베베 | Herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
KR20190082075A (en) * | 2017-12-29 | 2019-07-09 | 주식회사 누베베 | Method for manufacturing a herbal medicine tablet for using a weight loss agent |
US11395806B2 (en) | 2017-12-29 | 2022-07-26 | Nubebe Co., Ltd. | Herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
US11484514B2 (en) | 2017-12-29 | 2022-11-01 | Nubebe Co., Ltd. | Manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
KR101888471B1 (en) * | 2018-02-23 | 2018-08-14 | 주식회사 위드내추럴 | Compostions for reducing weight using herb medicine |
KR101888475B1 (en) * | 2018-02-23 | 2018-08-14 | 주식회사 위드내추럴 | Compostions for reducing weight using herb medicine |
Also Published As
Publication number | Publication date |
---|---|
KR101466862B1 (en) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101466862B1 (en) | Compositions for reducing weight | |
CN102742691B (en) | Health-care tea drink with blood pressure lowering effect and preparation method thereof | |
CN103520654A (en) | Chinese medicine composition for treating knee osteoarthritis and preparation method of Chinese medicine composition | |
CN103007215B (en) | Chinese medicinal composition for treating edema | |
KR20130009901A (en) | Health food composition for improving blood circulation, strengthening energy and preventing osteoporosis | |
CN106389881A (en) | Ointment capable of invigorating blood circulation and dissipating blood stasis | |
CN105031408A (en) | Health product for improving gout | |
CN104911086A (en) | Health wine for nourishing liver and kidney | |
CN104605372A (en) | Nutritional herbal cuisine based on cancer radiotherapy patient and preparation method thereof | |
CN104983886A (en) | Traditional Chinese medicine preparation for treating constipation and preparing method thereof | |
CN104799370A (en) | Health drink and preparation method thereof | |
CN104771637A (en) | Cholagogic and lithagogue agent for treating gallstone and preparation method thereof | |
CN104666587A (en) | Traditional Chinese medicine for preventing and treating hypertension | |
CN103705733A (en) | Chinese medicine capsule for treating arrhythmia and preparation method thereof | |
CN110876771A (en) | Motherwort herb paste and preparation method thereof | |
CN101810751B (en) | Chinese medicinal preparation for treating pediatric mesenteric lymph node inflammation | |
CN104984298A (en) | Traditional Chinese medicine preparation having weight-losing toxin-expelling efficacies | |
CN105902766A (en) | Peptic ulcer treating medicine and preparation method thereof | |
CN105851792A (en) | Peanut and sweet potato porridge capable of treating constipation caused by intestinal dryness, of old people and lying-in women | |
CN106310149A (en) | Qi and blood supplementing drug | |
CN105477566A (en) | Traditional Chinese medicine preparation for weight loss and detoxification | |
CN104958596A (en) | Traditional Chinese medicine composition for hernia patient | |
CN104800352A (en) | Traditional Chinese medicine for treating infantile anorexia | |
CN113398202A (en) | A Chinese medicinal composition with kidney invigorating effect, and its preparation method | |
CN110680849A (en) | Oral traditional Chinese medicine formula for treating bone fracture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20171127 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180917 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20191017 Year of fee payment: 6 |